Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-26 @ 2:12 AM
Study NCT ID:
NCT04517305
Status:
COMPLETED
Last Update Posted:
2021-06-18
First Post:
2020-08-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
Sponsor:
Fudan University
Organization:
Study Overview
Official Title:
Pyrotinib Plus Vinorelbine in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: